You just read:

Combination of Lenvatinib and Pembrolizumab Results in Notable Response Rates for Patients with Advanced Renal Cell Carcinoma Based on Interim Analysis of Ongoing Phase 1b/2 Trial

News provided by

Eisai Inc.

Sep 10, 2017, 08:30 ET